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Abstract
Detection of early tumor responses to treatment can give an indication of clinical outcome. Positron emission to-
mography measurements of the uptake of the glucose analog, [18F] 2-fluoro-2-deoxy-D-glucose (FDG), have demon-
strated their potential for detecting early treatment response in the clinic. We have shown recently that 13C magnetic
resonance spectroscopy and spectroscopic imaging measurements of the uptake and conversion of hyperpolarized
[1-13C]pyruvate into [1-13C]lactate can be used to detect treatment response in a murine lymphoma model. The pres-
ent study compares these magnetic resonance measurements with changes in FDG uptake after chemotherapy. A
decrease in FDG uptake was found to precede the decrease in flux of hyperpolarized 13C label between pyruvate and
lactate, both in tumor cells in vitro and in tumors in vivo. However, the magnitude of the decrease in FDG uptake and
the decrease in pyruvate to lactate flux was comparable at 24 hours after drug treatment. In cells, the decrease
in FDG uptake was shown to correlate with changes in plasma membrane expression of the facilitative glucose
transporters, whereas the decrease in pyruvate to lactate flux could be explained by an increase in poly(ADP-ribose)
polymerase activity and subsequent depletion of the NAD(H) pool. These results show that measurement of flux
between pyruvate and lactate may be an alternative to FDG–positron emission tomography for imaging tumor treat-
ment response in the clinic.
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Introduction
The introduction of new cancer therapies into the clinic, coupled with
the highly variable responses of individual patients to these treatments,
has stimulated the development of imaging methods that can give an
early indication of treatment response [1,2]. These would allow the
most appropriate therapy to be selected at an early stage during treat-
ment, with consequent welfare benefits for the patient and cost bene-
fits for the health-care system.
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Tumor responses to treatment are still largely assessed from mea-
surements of changes in tumor size [2]. However, this approach lacks
sensitivity because in many cases several weeks may elapse before there
is evidence of tumor shrinkage. An observable change in tumor size
might also not be detected despite a positive response to treatment,
e.g., after cytostatic therapy. Recent advances in our understanding of
tumor biology have resulted in the development of molecular-based
approaches for detecting response to therapy using targeted noninvasive
imaging methods [1–3].
Many tumors exhibit significantly increased glucose utilization in
comparison to normal tissue (the “Warburg effect”), which is thought
to be due largely to an increase in the expression and plasma mem-
brane presentation of the facilitative glucose transporters, primarily
the isoforms GLUT-1 and GLUT-3 [4]. In addition, there is increased
expression of the glycolytic enzymes, accompanied by a shift in glucose
metabolism from oxidative phosphorylation to glycolysis [5]. Increased
glucose uptake and phosphorylation have been exploited clinically to
detect tumors and their response to treatment using positron emission
tomography (PET). [18F] 2-Fluoro-2-deoxy-D-glucose (FDG), a glu-
cose analog labeled with the positron-emitting isotope, 18F, is taken
up by the cell through the GLUT transporters and is phosphorylated
to FDG–6-phosphate by hexokinase. Further metabolism is blocked
owing to the lack of a C-2 hydroxyl group, and FDG–6-phosphate
becomes trapped within the cell. Increased uptake of FDG by tumor
cells can thus be detected using PET [6]. Studies in lung [7], breast
[8], esophageal [9], lymphoma [10], and ovarian cancers [11] have
demonstrated that reduced FDG uptake can identify early treatment
response. FDG-PET, however, is not effective in all tumor types be-
cause some tumors, e.g., prostate adenocarcinoma, show low FDG
uptake [12], whereas in others, a high background uptake by sur-
rounding normal tissue can mask tumor uptake, for example, in the
brain [13] or in the presence of infected or inflamed tissue [14]. Fur-
thermore, after treatment, high uptake by infiltrating immune cells can
mask the decreased uptake by the dying tumor cells [15]. Quantitative
analysis of tumor metabolic activity (known as standardized uptake
value), can also pose problems and can be affected by a variety of dif-
ferent factors such as scanner resolution (making accurate estimation
of FDG uptake in tumors smaller than 3 cm difficult) [16], partial
volume effects caused by tumor heterogeneity [17], patient’s glucose
levels [18], and image acquisition and processing methods [19]. Thus,
there is a need to develop alternative and complementary techniques
for detecting tumor responses to treatment.
Dynamic nuclear polarization of 13C-labeled molecules can increase
their sensitivity of detection in a solution-state nuclear magnetic reso-
nance experiment by >10,000 times [20]. This dramatic increase in sen-
sitivity means that, after intravenous injection, the spatial distribution
of the labeled molecule and its subsequent metabolism can be imaged
in vivo using 13C magnetic resonance spectroscopic imaging (MRSI)
techniques. We have shown recently that the response of a murine lym-
phoma to drug treatment can be monitored by measuring the decrease
in label flux between hyperpolarized [1-13C]pyruvate and lactate in the
reaction catalyzed by lactate dehydrogenase (LDH) [21]. The decrease
in flux is likely to be due to a number of factors, including loss of enzyme
from the cell, a decrease in tumor cellularity, and decreases in tumor
lactate and NAD(H) concentrations. Because it has been proposed that
this technique could be translated into the clinic for response monitor-
ing [21], it is important to compare it with a molecular imaging tech-
nique that is used currently for this purpose in the clinic, FDG-PET.
In this study, we compare changes in both FDG uptake and flux of
hyperpolarized 13C label between pyruvate and lactate in mouse lym-




Tissue culture reagents, 2-(N -(7-nitrobenz-2-oxa-1,3-diazol-4-yl)
amino)-2-deoxyglucose (2-NBDG), SYTOX Red dead cell stain and
annexin V–Pacific Blue were from Invitrogen (Paisley, Refrewshire,
United Kingdom). All chemicals were of analytical grade from Sigma-
Aldrich, Co., Ltd. (Poole, Dorset, United Kingdom). Etoposide
(EPOSIN) was from PCH Pharmachemie (Haarlem, the Netherlands).
2-Fluoro-2-deoxy-D-[U-14C]glucose was and [14C]3-O-methylglucose
were from American Radiolabeled Chemicals, Inc. (St. Louis, MO),
and the poly(ADP-ribose) polymerase (PARP) assay kit was from
R&D Systems (Minneapolis, MN). Murine lymphoma (EL-4) cells
were from the European Collection of Cell Cultures (Salisbury, Wilt-
shire, United Kingdom).
Cell Culture
EL-4 cells were grown in RPMI 1640 medium, supplemented with
10% fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin, and
100 μg/ml streptomycin. Cell number and viability were monitored
using trypan blue staining. Cell death was induced by the addition
of etoposide (final concentration, 15 μM).
Detection of Cell Death In Vitro
Apoptosis and necrosis were visualized by staining with acridine
orange (5 μg/ml) and propidium iodide (25 μg/ml) [22]. For mea-
surements of cell death by flow cytometry, cell pellets (1 × 106 cells)
were washed in ice-cold HEPES-buffered saline (10 mM HEPES,
140 mM NaCl, 2.5 mM CaCl2, pH 7.4) and resuspended in 100 μl
of the same buffer. Annexin V–Pacific Blue was added (5 μl/100 μl of
cell suspension) in combination with SYTOX Red (5 nM), before
incubating for 10 minutes at 20°C. The resulting mixture was washed
once, kept briefly on ice, and then analyzed in an LSRII Cytometer
(BD Biosciences, Rockville, MD), with 20,000 cells counted per event.
Residual cell debris, identified on forward (FS) and side light scatter-
ing (SS) profiles, was excluded from the analysis by selective gating.
Cell death was also detected in the presence of the PARP inhibitor
3-aminobenzamide (3-AB; 10 mM).
Cell Uptake of [14C]FDG and 2-NBDG
[14C]FDG (7.4 kBq; specific radioactivity, 11.1 GBq/mmol; radio-
active concentration, 3.75 MBq/ml; radiochemical purity, 99%) was
added to cells (2 × 106) and incubated for 60 minutes at 37°C. Cells
were collected by centrifugation (1300g for 3 minutes), washed twice
with ice-cold PBS, and lysed in 0.2% SDS. FDG uptake was quan-
tified by scintillation counting using an LS 6500 liquid scintillation
counter (Beckman Coulter, Inc., Fullerton, CA). Uptake of 2-NBDG
was measured by flow cytometry. After etoposide treatment, cells (1 ×
106) were incubated for 60 minutes at 37°C in a growth medium
containing 2-NBDG (100 μM), washed twice with ice-cold HEPES-
buffered saline, and then analyzed in an LSRII Cytometer (BD Bio-
sciences), with 20,000 cells counted per event.
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Poly(ADP-Ribose) Polymerase Activity Assay
Cells (2 × 107) were treated with etoposide, washed and then ex-
tracted using 1× Passive Lysis Buffer (Promega UK, Ltd., Southampton,
Hampshire, United Kingdom) with Complete MINI EDTA-free pro-
tease inhibitor cocktail (Roche Applied Science, Mannheim, Germany)
for 30 minutes at 4°C. Poly(ADP-ribose) polymerase activity in the
resulting lysates was determined using the PARP Universal Colorimetric
Assay according to the manufacturer’s instructions. Protein content was
determined using Bradford’s reagent (Bio-Rad, Hercules, CA), and
specific PARP activity was expressed as activity per milligram of total
protein. One unit of PARP incorporates 100 pmol of poly(ADP-ribose)
from NAD+ into acid-insoluble form in 1 minute at 22°C.
Hexokinase Activity Assay
Hexokinase activity was determined as described in Bergmeyer
et al. [23]. The assay medium contained 39 mM triethanolamine,
216 mM D-glucose, 0.74 mM ATP, 7.8 mM magnesium chloride,
1.1 mM β-NADP+, 2.5 U of glucose-6-phosphate dehydrogenase,
pH 7.6. The assay was initiated by addition of 30 μl of a whole-cell
lysate (prepared as in the PARP activity assay), and the reaction was
followed spectrophotometrically at 340 nm. One unit of hexokinase
activity is defined as the amount of enzyme that will phosphorylate
1.0 μmol of D-glucose/min at 25°C.
Western Blots
Poly(ADP-ribose) polymerase cleavage and plasma membrane and
total expression of the glucose transporter isoforms, GLUT-1 and
GLUT-3, were assessed by Western blot analysis. Plasma membrane
proteins were fractionated using a kit from Biovision (Mountain
View, CA). The final protein pellet was resuspended in 0.5% SDS
in PBS. For whole-cell lysate preparation, cells were washed twice
in ice-cold PBS, solubilized in modified RIPA lysis buffer (50 mM
Tris pH 7.8, 150 mM NaCl, 5 mM EDTA, 15 mMMgCl2, 1% NP-
40, 0.5% sodium deoxycholate, 1 mM 1,4-dithioerythritol, 20 mM
N -ethylmaleimide), and passed five times through a 26G needle.
Cell debris was removed by centrifugation (16,100g, 5 minutes, 4°C).
Protein concentrations were determined using Bradford’s reagent (Bio-
Rad). A Non-Interfering Protein Assay kit (Merck Chemicals, Ltd.,
Darmstadt, Germany) was used to determine protein concentrations
in the purified plasma membrane fractions.
Proteins were resolved by SDS-PAGE on a 10% gel and transferred
on to polyvinylidene fluoride membranes (10 V, 30 minutes). Mem-
branes were probed using polyclonal rabbit anti–GLUT-1 (1:2500;
Abcam, Cambridge, Cambridgeshire, United Kingdom), polyclonal
goat anti–GLUT-3 antibodies (1:1000; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA), and polyclonal rabbit anti-PARP1 (1:1000;
Abcam). Antibodies for rabbit anti-HSP70 (1:2000; kindly provided
by Dr. Haley Whitaker) and rabbit antiactin (1:1000; Sigma-Aldrich,
Co., Ltd.) were used as loading controls. Peroxidase-conjugated donkey
anti–rabbit IgG (1:10,000; Jackson ImmunoResearch Europe, Ltd.,
Newmarket, United Kingdom) and peroxidase-conjugated rabbit
anti–goat IgG (1:4000; DarkoCytomation, Denmark) were used as
secondary antibodies. Proteins were visualized using the ECLplus
kit (GE Healthcare, Chalfont St Giles, Bucks, United Kingdom).
Blots were scanned (PowerLook III; Umax Systems GmbH, Willich,
Germany), and quantitation of the GLUT-3 signals was performed
by densitometry using a scanning analysis software (TotalLab TL120;
Nonlinear Dynamics, Newcastle upon Tyne, United Kingdom).
[1-13C]Pyruvate Hyperpolarization
A 44-mg sample of 91% [1-13C]pyruvic acid containing 15 mM
trityl radical OXO63 (GE Healthcare, Little Chalfont, United King-
dom) was hyperpolarized as described previously [20,21]. The frozen
sample was dissolved at 180°C in 6 ml of buffer containing 40 mM
HEPES, 94 mM NaOH, 30 mM NaCl, 50 mg/L EDTA, pH 12.5.
The sample was dissolved in less than 10 seconds, and polarization
levels were between 18% and 25%.
Nuclear Magnetic Resonance Spectroscopy of Cells
Cells (1 × 108) in RPMI 1640 medium were examined in a 10-mm
nuclear magnetic resonance tube, using a broadband probe (Varian
NMR Instruments, Palo, Alto, CA) in a 9.4-T vertical wide-bore mag-
net (Oxford Instruments, Abingdon, Oxfordshire, United Kingdom).
The sample temperature was maintained at 37°C. Hyperpolarized
[1-13C]pyruvate (75 mM) and nonhyperpolarized, unlabeled lactate
(75 mM) were injected into the cell suspension, and single-transient
13C spectra were acquired every second for 400 seconds, using a 6° flip
angle pulse and a spectral width of 32 kHz.
Tumor Implantation
Female C57BL/6 mice (Charles River, Ltd., Wilmington, MA), at
an age of 6 to 8 weeks, were injected subcutaneously (in the lower
flank) with 5 × 106 EL-4 cells, and the tumors were allowed to grow
for 10 days (volume, ∼2 cm3) [24]. Mice were treated with an intraperi-
toneal injection of 67 mg of etoposide/kg body weight. All procedures
were carried out in accordance with the Animals (Scientific Procedures)
Act of 1986 (UK) and were designed with reference to the UK Co-
ordinating Committee on Cancer Research Guidelines for the Welfare
of Animals in Experimental Neoplasia. Tumor cell death was assessed
histologically, using the National Institutes of Health ImageJ program
to estimate the fraction occupied by the fragmented nuclei of dead cells
in a 1.2-mm2 field of view in tumor sections stained with hematoxylin
and eosin [24]. Tumor size was reported as the product of the two largest
perpendicular diameters (mm2).
Tumor Uptake of [14C]FDG
Mice were anesthetized with an intraperitoneal injection of 10 ml/
kg body weight of a 5:4:31 mixture of Hypnorm (VetaPharma, Ltd.,
Leeds, West Yorkshire, United Kingdom), Hypnovel (Roche, Basel,
Switzerland), and saline and were injected intravenously with 14.8 kBq
of [14C]FDG in sterile saline. Tumor FDG uptake was measured at
60 minutes after injection. Mice were euthanized by cervical dislocation,
and the tumors were excised and homogenized in RIPA buffer (150mM
NaCl, 1.0% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS,
50 mM Tris, 1 mM EDTA, pH 8.0; 10 ml of buffer/g of tumor tis-
sue) using a General Laboratory Homogenizer (OMNI International,
Warrenton, VA) and incubated at 24°C for 30 minutes. Cell debris
was removed by centrifuging at 3000g for 10 minutes. The resulting
supernatant was retained, and [14C]FDG uptake was quantified by
liquid scintillation counting.
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Nuclear Magnetic Resonance Spectroscopy of Tumors
Mice were anesthetized, and a catheter was inserted into a tail vein. A
25-mm-diameter surface coil tuned to 13C (100 MHz) was positioned
over the tumor. The entire assembly was placed in a quadrature
1H-tuned volume coil (Varian), in a 9.4-T vertical wide-bore magnet.
Transverse 1H images were acquired from the tumor using a spin-echo
pulse sequence (repetition time, 1.5 seconds; echo time, 30milliseconds;
field of view, 32 mm × 32 mm; data matrix, 256 × 256; slice thickness,
2 mm; 11 slices). After injection of hyperpolarized [1-13C]pyruvate,
which was accomplished within 3 seconds, 128 single-transient spectra
were collected from a 5-mm-thick tumor slice for a period of 128 sec-
onds (every 16th spectrum was collected from the entire sensitive vol-
ume of the surface coil). Spectra were acquired using a slice-selective
600-microsecond sinc pulse, with a nominal flip angle of 5°.
Estimation of Hyperpolarized 13C Label Flux between
Pyruvate and Lactate
The peak intensities of hyperpolarized [1-13C]lactate and [1-13C]
pyruvate were fitted to the modified Bloch equations for a two-site
exchange to obtain a rate constant for flux of label between pyruvate
and lactate (kP). The limitations of this model for estimating flux
have been discussed previously [21].
Statistics
Results are expressed as the mean ± SEM. Significant differences be-
tween mean values were determined by analysis of variance (ANOVA)
followed by Dunnett’s post hoc test. Differences between treatment
groups were considered significant if P < .05.
Results
Measurement of Cell Death In Vitro
Cell death was analyzed by flow cytometry of cells that had been
stained with annexin V–Pacific Blue, which labels apoptotic and ne-
crotic cells, and SYTOX Red dead cell stain, which labels necrotic cells
(Figure 1). The onset of apoptosis was detectable at 8 hours after treat-
ment (77% ± 8% increase in median fluorescence, n = 4, P < .01),
rising to a maximum at 16 hours (920% ± 130% increase; Figure 2A).
The necrotic cell fraction remained largely unchanged throughout the
treatment time course, with a significant increase in necrosis becoming
detectable at 16 hours (P < .05). Similar results were obtained by fluo-
rescence microscopy of cells stained with acridine orange and propidium
iodide (data not shown).
Measurements of Hyperpolarized [13C] Label Flux between
Pyruvate and Lactate in Cells
Addition of hyperpolarized [1-13C]pyruvate to cells resulted in an
increase in the lactate carboxyl signal intensity, because the label was
transferred from pyruvate, followed by a decrease in signal intensity
due to decay of the polarization (Figure 3). Changes in the rate con-
stant describing the flux between [1-13C]pyruvate and [1-13C]lactate
(kP) were observed in cells after the induction of apoptosis by etoposide
treatment. A 23% decrease was detected at 12 hours after treatment,
although the decrease in the rate did not reach statistical significance
until 14 hours (P < .01). By 16 hours, the rate constant had fallen from
3.6 × 10−4 ± 0.6 × 10−4 s−1 to 0.6 × 10−4 ± 0.1 × 10−4 s−1, a decrease
of 83% (P < .01; Figure 2B, right axis). The fitted values for the rate
constant kP, the values for the rate constant describing flux between
[1-13C]lactate and [1-13C]pyruvate (kL), and the apparent spin lattice
relaxation rates for [1-13C]lactate (ρL) and [1-
13C]pyruvate (ρP), which
were assumed to be equal, are shown in Table W1.
The decreased pyruvate–lactate flux in etoposide-treated EL-4 cells
has been shown previously to be due predominantly to PARP-mediated
depletion of the NAD(H) pool [21] because inhibition of PARP largely
prevented the decrease in the rate constant kP. We have demonstrated
here a temporal correlation between PARP-mediated depletion of
NAD(H) and the loss of flux between pyruvate and lactate in drug-
treated cells (Figures 1B and 2C ). NAD(H) depletion was assessed from
the loss of cellular UVautofluorescence (excitation at 350 nm; emission
at 475 nm). Cytoplasmic NADH has been shown previously to make a
significant contribution to this autofluoresence [25], and it is the cyto-
solic, rather than the mitochondrial NAD(H) pool, that is depleted
after PARP activation [26]. There was a significant decrease in auto-
fluorescence by 10 hours after drug treatment (58% decrease, P <
.01), a time at which there had been a significant increase in PARP
activity (238% increase, P < .05). Poly(ADP-ribose) polymerase activity
rose to a peak at 14 hours after treatment, which was five-fold greater
than that of the control, untreated cells. Cellular autofluorescence de-
clined to a minimum at 12 hours. Addition of a PARP inhibitor, 3-AB,
inhibited loss of cellular UV autofluorescence after drug treatment,
confirming that the UV autofluorescence correlates with the cytosolic
Figure 1. Flow cytometric analysis of EL-4 cells treated for 16 hours
with etoposide. (A) Detection of apoptotic cells using annexin V–-
Pacific Blue (λ Ex/Em = 410/455) and necrotic cells by SYTOX Red
nuclear staining (λ Ex/Em = 640/658). (B) Changes in cellular auto-
fluorescence after treatment. The autofluorescence observed at
455 nm with excitation at 350 nm has been assigned to NADH
[25,26]. Population 1 represents viable cells, whereas population 2
represents apoptotic cells that have a low UV autofluorescence
and stain with annexin V. Population 3 represents necrotic cells.
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NADH concentration. The median fluorescence of cells treated with
etoposide and 3-AB for 16 hours was 92% ± 14% (n = 4) of the un-
treated control cells.
Caspase 3–mediated cleavage of PARP was evaluated by Western
blot analysis of whole-cell lysates (Figure 4). The cleaved 25-kDa PARP
fragment was detected 6 hours after treatment after prolonged exposure
of the blot, with levels of cleaved PARP increasing throughout the
remainder of the time course.
FDG Uptake in Cells
Uptake of FDG was measured during a period of 16 hours after
etoposide treatment (Figure 2B, left axis). [14C]FDG was added to
treated cells, and its intracellular accumulation was measured after
60 minutes. A 22% reduction in uptake (adjusted for cell number)
was observed at 6 hours after drug treatment, falling from 6.7 ±
0.3 pmol/107 cells in untreated cells to 5.2 ± 0.4 pmol/107 in treated
cells (n = 9, P < .01). The uptake rate dropped steadily during the
following 10 hours, to 10% of the FDG uptake rate in untreated cells
by 16 hours (0.7 ± 0.05 pmol/107 cells). The uptake of a fluorescent
glucose analog, 2-NBDG [27], was also evaluated by flow cytometry.
This showed a similar profile to FDG of reduced uptake as a function
of time (Figure W1).
To test whether changes in FDGuptake were a result of changes in the
transport rate or subsequent phosphorylation, both hexokinase activity
and glucose transporter expression were measured as a function of time
after etoposide treatment (Figure 2D). There was no significant change
in extractable hexokinase activity during the 16 hours after drug treat-
ment. Treatment with etoposide resulted in minimal changes in both
GLUT-1 and GLUT-3 expression in whole-cell lysates during 16 hours
after drug treatment (Figure 5A); however, there was a decrease in
GLUT-1 and GLUT-3 levels in the plasma membrane fraction at
6 hours, which further decreased throughout the remainder of the treat-
ment time course, closely paralleling the pattern of reduced FDG uptake
after treatment (Figures 2D and 5B). These results suggest that etoposide
treatment causes the glucose transporters to translocate from the plasma
membrane to the cytosol, resulting in a decrease in FDG uptake.
Monitoring Treatment Response in Tumors
Intravenous injection of hyperpolarized [1-13C]pyruvate (0.2 ml,
75 mM) into EL-4 tumor-bearing mice resulted in the appearance
of signals from [1-13C]pyruvate and [1-13C]lactate in the tumors (Fig-
ure 3). Treatment with etoposide for 16 and 24 hours resulted in 15% ±
2% and 31% ± 4% cell death, respectively, in comparison to 4% ± 1%
in untreated tumors (n = 3), as assessed by histological analysis of tumor
sections obtained postmortem. Drug treatment resulted in a reduction in
tumor volume from 282 ± 16 to 251 ± 15 mm2 at 16 hours after treat-
ment (11% decrease, P > .05, n = 5), decreasing further to 199 cm ±
13 mm2 at 24 hours after treatment (30% decrease, P < .01, n = 5).
There was no significant change in flux between pyruvate and lactate at
16 hours after treatment (n = 5 animals), but by 24 hours, there was a
38% decrease in the rate constant kP, from 0.056 ± 0.005 s
−1 (n =
5 animals) to 0.034 ± 0.006 s−1 (P < .05, n = 6 animals; Figure 6A).
The fitted values for the rate constants kL and kP and the apparent spin
lattice relaxation rates (ρL and ρP) are shown in Table W2.
[14C]FDG uptake was measured in tumors after drug treatment
(Figure 6B). Measurements of FDG uptake in excised tissue show good
agreement with PETmeasurements of FDG uptake [28]. There was a
Figure 2. Changes in cell metabolism after etoposide-induced apop-
tosis of EL-4 cells. (A) Apoptosis (•) and necrosis (○) determined
by flow cytometry. Apoptotic cells were detected using annexin V–
Pacific Blue (λ Ex/Em= 410/455) and necrotic cells using SYTOX Red
nuclear staining (λ Ex/Em = 640/658). (B) Changes in [1-13C]pyruvate
to [1-13C]lactate flux (▪) and [14C]FDG uptake (□) after etoposide
treatment. The rate constants for label flux from pyruvate to lactate
(kP) were derived by fitting changes in signal peak intensity to the
modified Bloch equations for two-site exchange [21]. Cell number–
corrected uptake of [14C]FDG was measured in cells at 60 minutes
after adding the radiotracer. (C) Changes in cellular autofluorescence
(▵) and PARP activity (▴) in etoposide-treated cells. UV autofluores-cence was detected by flow cytometry (λ Ex/Em = 350/455), and
PARPactivity byELISA. (D)Hexokinase activity (⋄) andGLUT-3 plasma
membrane expression (♦) in treated EL-4 cells. Hexokinase activity in
cell lysates was determined by measuring the reduction of NADP+ in
a coupled reaction with glucose-6-phosphate dehydrogenase, as
described in Bergmeyer et al. [23]. GLUT-3 levels in plasma mem-
brane protein fractions were assessed by Western blot. Quantita-
tion of bands was determined by densitometry and expressed as a
percentage of GLUT-3 expression in untreated cells. Data shown as
mean ± SEM (n = 3-5).
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16% decrease in FDG uptake at 16 hours after treatment, falling from
12.7% ± 0.6% injected dose per gram of tissue (ID/g) to 10.6% ±
0.6% ID/g (P < .05, n = 6 animals). At 24 hours, FDG uptake was
7.9% ± 0.6% ID/g (P < .001, n = 12 animals), 38% lower than the
pretreatment uptake value (n = 11 animals).
Discussion
There is a pressing need to develop noninvasive imaging techniques
for monitoring tumor treatment response in the clinic. FDG-PET has
been shown to be a good predictive indicator of treatment response in
a variety of different human cancers [7–11]; however, this technique
has low sensitivity in slowly growing tumors with low metabolic ac-
tivity (such as prostate adenocarcinoma) and measurements of tumor
uptake may be difficult when surrounding normal tissue has high
glucose metabolism (e.g., in the brain) [12,13]. We have recently re-
ported an alternative method for detecting treatment response, which
measures the decrease in the rate of LDH-catalyzed flux of hyper-
polarized 13C label between pyruvate and lactate using MRSI [21].
In this study, we compared the temporal changes in FDG uptake with
those of hyperpolarized 13C label flux between pyruvate and lactate in
a murine lymphoma model after drug treatment.
Treatment with the topoisomerase type II inhibitor, etoposide, re-
sulted in the induction of apoptosis in EL-4 cells in vitro. A reduction
in FDG uptake was detected 6 hours after treatment, which occurred
2 hours before the exposure of the phospholipid, phosphatidylserine,
and consequent binding of annexin V. This reduction in FDG uptake
correlated with the translocation of both GLUT-1 and GLUT-3 trans-
porters from the plasma membrane to the cytosol, as shown byWestern
blots of the whole cell and plasma membrane fractions. There were no
Figure 4. Caspase 3–mediated PARP cleavage after etoposide treat-
ment. Western blot analysis of the levels of uncleaved (113 kDa) and
cleaved PARP (25 kDa) in whole-cell lysates of etoposide-treated
cells during a 16-hour time course. The blot was also subjected to
a prolonged exposure to identify the onset of caspase 3–mediated
PARP cleavage. Actin was used as a loading control.
Figure 3.Measurements of hyperpolarized 13C label flux between pyruvate and lactate in cells and in tumors. Sequential 13C spectra from
cells (A) and a tumor (C), showing signals from hyperpolarized [1-13C]pyruvate (at 171 ppm) and [1-13C]lactate (at 183 ppm). The peaks at
206 ppm in (A) are from natural abundance [2-13C]pyruvate. Example of fits of the [1-13C]pyruvate and [1-13C]lactate peak intensities from
the cell (B) and tumor spectra (D) to a two-site exchange model [21]. Fits are shown as solid lines. The pyruvate peak intensity was divided
by 100 in (B). For clarity, only every fourth data point is shown. AU indicates arbitrary units.
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changes in the whole-cell levels of GLUT-1 or GLUT-3 or in the activity
of hexokinase during the 16-hour time course. Previous studies in non–
small cell lung cancer cells in vitro have shown that changes in plasma
membrane glucose transporter expression can explain a reduction in
FDG uptake after inhibition of epidermal growth factor receptor kinase
[29]. Inhibition of epidermal growth factor receptor kinase results in
inhibition of Akt (PKB) activity, which is known to enhance and main-
tain glucose transporter presentation on the plasma membrane [30].
The decrease in the plasma membrane presentation of GLUT-1 and
GLUT-3 observed here might also be due to a decrease in Akt activity
because Akt is known to be a substrate for caspases [31], and caspase-
cleaved PARP first became evident at 6 hours after drug treatment
(Figure 4) when there was also a decrease in GLUT-3 expression at
the plasma membrane and a corresponding decrease in FDG uptake
(Figure 2). The results obtained here, however, are in contrast to those
obtained in pro–B-lymphocytic cells, where, after exposure to a range
of genotoxic agents, including etoposide, a decrease in GLUT-1 and
GLUT-3 expression was observed [32].
In contrast to the relatively early reduction in FDG uptake rate, the
decrease in LDH-catalyzed flux of hyperpolarized 13C label between
pyruvate and lactate was not significant until 14 hours after drug treat-
ment. We have shown previously that the decrease in label flux
between pyruvate and lactate in EL-4 lymphoma cells in vitro could
be explained predominantly by PARP-mediated depletion of the NAD
(H) coenzyme pool because PARP inhibitors prevented the decrease
in NAD(H) concentration, as determined from 31P MRSI measure-
ments on cells extracts, and also largely prevented the decrease in flux
at 16 hours after drug treatment [21]. We have shown here a temporal
correlation between measured PARP activity and a decrease in cellular
UV autofluorescence, which is representative of the cytoplasmic
NADH concentration [25,26]. There was a gradual increase in PARP
activity after etoposide treatment, rising rapidly at 10 hours after treat-
ment, by which time there was a significant decrease in cellular auto-
fluorescence. Although the decrease in autofluorescence preceded the
decrease in flux between pyruvate and lactate, this may reflect the Km
of the enzyme for NAD(H), the enzyme being saturated with the
coenzymes in untreated cells. The decrease in flux between pyruvate
and lactate may be delayed by caspase 3–mediated cleavage of PARP
(Figure 4), which is known to result in PARP inactivation [33]. In
summary, in cells, the observed decrease in flux between pyruvate
and lactate is associated with an increase in PARP activity and a sub-
sequent decrease in the cellular NAD(H) pool.
The temporal changes in FDG uptake and hyperpolarized 13C
label flux were also evaluated in EL-4 tumors that had been produced
by subcutaneous implantation of EL-4 cells. We had demonstrated
previously, by measurements at a single time point, that hyperpolar-
ized 13C label flux between pyruvate and lactate was decreased at
24 hours after drug treatment and had shown that this was likely
to be due to a number of factors, including a decrease in tumor lac-
tate concentration, a reduction in tumor cellularity, and a loss of the
enzyme from the cells as well as the coenzyme NAD(H) [21].
In the current study, we have shown that a significant decrease in
FDG uptake was detectable at 16 hours after etoposide treatment,
but the decrease in flux between pyruvate and lactate did not reach
statistical significance until 24 hours after treatment when a significant
decrease in tumor volume was observed. Therefore, both in isolated
cells and in tumors in vivo, the decrease in FDG uptake preceded
the decrease in flux of 13C label between pyruvate and lactate in this
lymphoma tumor model.
Figure 6. Comparison of [14C]FDG uptake with hyperpolarized 13C
label flux between pyruvate and lactate in EL-4 tumors. (A) Changes
in [1-13C]pyruvate to [1-13C]lactate flux in untreated EL-4 tumors and
tumors treated with etoposide for either 16 or 24 hours. Changes
in tumor pyruvate and lactate peak intensities were fitted to a two-
site exchange model to obtain the rate constant for pyruvate to
lactate flux. (B) Uptake of [14C]FDG in untreated EL-4 tumors and
tumors treated with etoposide for either 16 or 24 hours. [14C]FDG
was injected intravenously, and uptake was allowed to proceed for
60 minutes. Tumors were then excised and homogenized. Percent-
age injected dose per gram of tissue (%ID/g) was determined by
liquid scintillation counting. Mean values (n = 6-12) and SEs are
shown (*P < .05, **P < .01).
Figure 5. Effect of etoposide on glucose transporter membrane ex-
pression. Western blot analysis of GLUT-1 and GLUT-3 levels in
whole-cell lysate (A) and plasma membrane protein fractions (B) of
etoposide-treated cells during a 16-hour time course after drug treat-
ment. HSP70 and actin were used as loading controls.
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A reduction in FDG uptake has been measured in the clinic as
early as 24 hours after the first dose of chemotherapy, with the early
PET response able to predict the later response with PET at day 8 in
all patients [34]. These results, coupled with the results found in this
study, indicate that some benefit may be derived from monitoring
treatment response with FDG-PET at an early stage after treatment.
However, there are other studies in which FDG uptake was reduced
for a period of 2 weeks before increasing again in patients that failed
to respond to therapy [35]. Conversely, false-positive results have also
been detected early after therapy, and these are thought to correlate
with an influx of inflammatory cells [15]. It is now generally accepted
that scans performed 5 to 6 weeks after therapy are more accurate at
indicating response than early monitoring [36–38]. In this context,
the earlier detection of response that we have seen here with FDG
may have no advantage in the clinic over the later detection of re-
sponse using hyperpolarized 13C-labeled pyruvate.
Although the timing of response to treatment may vary between
FDG-PET and hyperpolarized 13C, the fractional decrease in flux
between pyruvate and lactate is nearly identical to the decrease in
FDG uptake. This suggests that the magnetic resonance experiment
could be as sensitive as the PET experiment for detecting treatment
response. Moreover, MRSI avoids the use of ionizing radiation. The
most important advantage of the technique, however, may be in assess-
ing response in cancers, e.g., tumors of the brain and prostate, where
FDG-PET is ineffective in measuring treatment response. A recent
study in a transgenic mouse model of prostate cancer showed that
changes in pyruvate to lactate flux can be used to predict response
to antiandrogen therapy. In responding tumors, a reduction in pyru-
vate to lactate flux correlated with a reduction in tumor volume and an
increase in mean survival time after hormone deprivation, with an in-
crease in flux and tumor volume observed in the nonresponders [39].
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Table W1. Fitted Rate Constants for Untreated and Etoposide-Treated Cells.
kL (×10
−3 s−1) kP (×10
−3 s−1) ρL = ρP (s
−1)
Untreated (n = 4) 8 ± 1 0.36 ± 0.03 0.027 ± 0.001
2 h (n = 5) 20 ± 4 0.30 ± 0.02 0.026 ± 0.001
4 h (n = 6) 13 ± 2 0.35 ± 0.02 0.027 ± 0.000
6 h (n = 6) 21 ± 2* 0.31 ± 0.03 0.024 ± 0.002
8 h (n = 6) 18 ± 2 0.33 ± 0.03 0.025 ± 0.001
10 h (n = 5) 18 ± 3 0.34 ± 0.04 0.025 ± 0.002
12 h (n = 4) 8 ± 1 0.30 ± 0.03 0.023 ± 0.002
14 h (n = 4) 7 ± 2 0.21 ± 0.01* 0.024 ± 0.001
16 h (n = 4) 6 ± 2 0.06 ± 0.01† 0.027 ± 0.001
Values are presented as mean ± SEM.
*P < .05, ANOVA followed by Dunnett’s post hoc test.
†P < .01, ANOVA followed by Dunnett’s post hoc test.
Figure W1. Flow cytometric analysis of 2-NBDGuptake in etoposide-
treated EL-4 cells. (A) Dual-plot histogram of 2-NBDG uptake and
SYTOX Red staining in 16-hour treated and untreated cells. Cells
were incubatedwith 2-NBDG (100 μM) for 60minutes at 37°C before
the determination of uptake by flow cytometry (2-NBDG λEx/Em =
465/540 nm; SYTOX Red λEx/Em = 640/658). Population 1 repre-
sents viable cells, population 2 represents apoptotic cells, and popu-
lation 3 represents necrotic cells. (B) Quantitation of 2-NBDG uptake
after treatment. 2-NBDG uptake was expressed as the percent-
age change in median fluorescence. Mean values (n = 4) and SEM
are shown.
Table W2. Fitted Rate Constants for Untreated and Etoposide Treated Tumors.
kL (s
−1) kP (s
−1) ρL = ρP (s
−1)
Untreated (n = 5) 0.018 ± 0.002 0.056 ± 0.005 0.030 ± 0.001 (34 ± 1 s)
Treated 16 h (n = 5) 0.023 ± 0.001 0.063 ± 0.006 0.031 ± 0.001 (32 ± 1 s)
Treated 24 h (n = 6) 0.022 ± 0.004 0.034 ± 0.006* (−38%) 0.032 ± 0.001 (32 ± 2 s)
Values are presented as mean ± SEM.
*P < .05, ANOVA followed by Dunnett’s post hoc test.
